Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,414 across all filing types
Latest filing 2026-06-15 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
TRUQAP APPROVED IN US FOR PROSTATE CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC for a foreign issuer, AstraZeneca PLC, reporting a regulatory approval (Truqap approved in the US for prostate cancer). It contains detailed information about the drug approval, clinical trial results, and labels the report as pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act, consistent with Form 6-K filings. Form 6-K filings are regulatory filings used to report material information between annual reports (such as Form 20-F). There are no actual financial statements or earnings data in this document; it is essentially a material business update announcement. Therefore, the appropriate category is Regulatory Filings (RNS), which is the fallback category for Form 6-K filings that do not fit other categories.
2026-06-15 English
Truqap approved in US for prostate cancer
Regulatory Filings Classification · 95% confidence The document is a press release by AstraZeneca dated 15 June 2026 announcing FDA approval of their drug Truqap combination for a specific prostate cancer indication, based on results of the CAPItello-281 Phase III clinical trial. It includes detailed clinical trial results, safety profile, background on the disease and drug, and future regulatory submission plans. The report is not a financial statements filing, not a management or earnings report, does not include any shareholder vote or board changes information, nor is it a legal or financing update. It is a typical corporate announcement about a clinical trial result and regulatory approval. The document is about product approval and trial results, classified within equity regulatory announcements and does not match the definitions of financial or governance reports. The length (13,850 chars) suggests it is a full announcement, not just a brief notice or report publication announcement. Since it is a regulatory announcement of drug approval and trial results impacting the company, the best fit category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other specific categories.
2026-06-15 English
AstraZeneca Finance LLC;AstraZeneca PLC - Base prospectus (debt)
Capital/Financing Update Classification · 85% confidence The document is a Base Prospectus for AstraZeneca’s Euro Medium Term Note Programme, detailing terms and conditions for the issuance of debt securities. It is a financing document for capital raising rather than an annual report, earnings release, or board announcement. This matches the definition of a Capital/Financing Update.
2026-06-11 English
Admission of Further Securities to Trading
Share Issue/Capital Change Classification · 85% confidence The document is a short RNS announcement titled “Notification of Admission of Further Securities to Trading” indicating that AstraZeneca is admitting newly issued ordinary shares (14,120 shares) under its employee share schemes to trading on the London Stock Exchange. It details the number of securities issued, total in issue, admission dates, and fungibility. This is an announcement of a share issuance/capital change event, matching the definition of Share Issue/Capital Change (SHA).
2026-06-01 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 93% confidence The document is an RNS announcement titled “Total Voting Rights,” reporting the number of issued ordinary shares and total voting rights in accordance with UK FCA Disclosure and Transparency Rule 5.6.1. It is a formal announcement of voting rights, not a report or financial statements. This fits the Declaration of Voting Results & Voting Rights Announcements category.
2026-06-01 English
ADMISSION OF FURTHER SECURITIES TO TRADING
Share Issue/Capital Change Classification · 90% confidence The document is an SEC Form 6-K “Report of Foreign Issuer” by AstraZeneca PLC. It announces the admission of further ordinary shares to trading under the company’s existing block admission (i.e., a new share issue/capital change), with no financial statements or broader report content. This fits the “Share Issue/Capital Change” category (Code: SHA).
2026-06-01 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.